Related Experiment Videos

Treatment of chronic muco-cutaneous candidiasis by lymphocyte transfer factor

Australian and New Zealand Journal of Medicine
|August 1, 1975
PubMed

Insights

Lymphocyte transfer factor therapy showed clinical benefits for chronic mucocutaneous candidiasis patients. This immunotherapy, combined with antifungal drugs, helped maintain remission in patients with impaired immune function.

Area of Science:

  • Immunology
  • Dermatology
  • Infectious Diseases

Background:

  • Idiopathic chronic mucocutaneous candidiasis is a debilitating fungal infection.
  • Some cases present with a familial pattern, suggesting a genetic component.
  • Patients often exhibit dermal anergy and impaired cellular immunity.

Purpose of the Study:

  • To evaluate the clinical efficacy of lymphocyte transfer factor in treating chronic mucocutaneous candidiasis.
  • To assess the role of transfer factor in managing patients with impaired immune responses.
  • To determine if transfer factor can maintain remission when combined with antifungal chemotherapy.

Main Methods:

  • Six patients with early-onset chronic mucocutaneous candidiasis received lymphocyte transfer factor.
  • Patients were treated with antifungal chemotherapy.
  • Therapy effectiveness was monitored using Candida skin tests and clinical assessment.
  • Immune function, including migration inhibition factor production, was assessed.

Main Results:

  • Lymphocyte transfer factor administration demonstrated a beneficial clinical effect in patients.
  • Antifungal chemotherapy was effective in reducing or clearing candidiasis.
  • Repeated transfer factor injections helped maintain remission.
  • Candida skin tests were used to monitor therapeutic response.

Conclusions:

  • Lymphocyte transfer factor is a potentially effective therapeutic agent for chronic mucocutaneous candidiasis.
  • Transfer factor therapy, alongside conventional antifungal treatment, can induce and maintain remission.
  • This immunotherapy may be particularly useful in patients with compromised cellular immunity.

Related Concept Videos